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Abstract In recent years, substantial advances have been
achieved in the treatment of mucormycosis. It is now clear
that early initiation of therapy results in substantially better
outcomes, underscoring the need to maintain a high index
of suspicion and aggressively biopsy potential lesions.
Increasing data support the need for surgical excision of
infected and/or necrosed tissue whenever feasible. Based on
their superior safety and efficacy, lipid formulations of
amphotericin B have become the standard treatment for
mucormycosis. Posaconazole may be useful as salvage
therapy, but cannot be recommended as primary therapy for
mucormycosis based on available data. Pre-clinical and
limited retrospective clinical data suggest that combination
therapy with lipid formulations of amphotericin and an
echinocandin improves survival during mucormycosis. A
definitive trial is needed to confirm these results. The use of
the iron chelator, deferasirox, as adjunctive therapy also
improved outcomes in animal models of mucormycosis.
However, its efficacy was not confirmed in a recent, phase
2 clinical trial. Additional study is required of the potential
for abrogation of iron acquisition as adjunctive treatment of
mucormycosis. Combination polyene-posaconazole therapy
was of no benefit in pre-clinical studies. Adjunctive therapy
with recombinant cytokines, hyperbaric oxygen, and/or
granulocyte transfusions can be considered in selected
patients. Large-scale, prospective, randomized clinical trials
are needed to define optimal management strategies for
mucormycosis.
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Introduction
Mucormycosis is a life-threatening infection caused by
fungi of the order Mucorales. Recent re-classification has
abolished the class Zygomycetes and placed the order
Mucorales in the subphylum Mucormycotina [1]. There-
fore, we refer to infection caused by Mucorales as
mucormycosis rather than zygomycosis.
Mucormycosis typically occurs in patients with diabetes
mellitus, organ or hematopoietic stem cell transplantation
(HSCT), neutropenia, or malignancy [2, 3]. The incidence
of mucormycosis appears to be increasing, based on data
from cancer centers in the United States and Europe [2, 4–
8] and PubMed publications [9]. Furthermore, a recent,
comprehensive, population-based epidemiology study
found a near doubling of the frequency of mucormycosis
cases throughout France over a 10-year period (1997–2006)
[10].
For decades, the mortality rate of mucormycosis has
remained ≥40% despite aggressive surgical and antifungal
therapy [2, 3, 7, 11–14]. In patients with hematologic
malignancy or HSCT, mortality rates exceed 65% and 90%,
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DOI 10.1007/s11908-010-0129-9respectively. Mortality rates exceed 65% in patients with
hematologic malignancy, and in those with HSCT,
mortality rates exceed 90%. However, recent translational
research, funded by the US National Institutes of Health
and by the pharmaceutical industry, has resulted in
several new treatment strategies for mucormycosis,
raising the possibility of improving outcomes based on
superior medical therapy.
Background Treatment Strategies for Mucormycosis
The successful treatment of mucormycosis requires four
steps: 1) early diagnosis; 2) reversal of underlying predis-
posing risk factors, if possible; 3) surgical debridement
where applicable; and 4) prompt antifungal therapy [3].
Early Diagnosis
A recent study from Chamilos et al. [15￿￿] quantified the
benefit of early initiation of polyene antifungal therapy.
They reported that if treatment was initiated within 5 days
of diagnosis of mucormycosis, survival was markedly
improvedcomparedtoinitiationofpolyenetherapyat≥6da ys
after diagnosis (83% vs 49% survival). Hence, establishing an
early diagnosis of mucormycosis is critical to enable early
initiation of active antifungal therapy.
The development of other diagnostic methods is a major
unmet need for this infection. Development of quantitative
polymerase chain reaction systems is a promising area of
ongoing research to enable more rapid diagnosis [16–19].
The most common finding by CT scanning of patients with
rhino-orbital-cerebraldiseaseissimplysinusitis,soabsenceof
deeper infection by CT scan does not rule out mucormycosis
[20￿￿]. MRIs are more sensitive than CT scans for detecting
orbital and central nervous system (CNS) involvement
[20￿￿]. CT scans are useful for early detection of pulmonary
mucormycosis, particularly in patients with cancer. By
logistic regression, pulmonary mucormycosis in patients
with cancer could be distinguished from aspergillosis on
the basis of sinusitis, presence of multiple (≥10) nodules by
CT scan, and pleural effusion [21].
Reversal of Underlying Disease
It is critical to reverse/prevent underlying defects in host
defense when treating patients with mucormycosis. Immuno-
suppressive medications, particularly corticosteroids, should
be dose reduced or stopped if at all possible. Aggressive
management to rapidly restore euglycemia and normal acid-
base status is critical in diabetic patients in ketoacidosis.
Administration of iron should be avoided, because it
exacerbates the severity of infection in animal models of
mucormycosis [22, 23, 24￿￿]. For the same reason, it may be
advisable to minimize blood transfusions, if feasible.
Surgical Management
Blood vessel thrombosis and resulting tissue necrosis
during mucormycosis can result in poor penetration of
antifungal agents to the site of infection. Therefore,
debridement of necrotic tissues may be critical for complete
eradication of mucormycosis. In a recent study, surgery was
found to be an independent variable by logistic regression
for favorable outcome in patients with mucormycosis [2].
Furthermore, in multiple case series, patients who did not
undergo surgical debridement of mucormycosis had a far
higher mortality rate than patients who underwent surgery
[5, 25–32]. Although there is potential selection bias in
these case series, as patients who did not undergo surgery
likely differed in disease severity or comorbidities from
those who did, these data support the concept that surgical
debridement is necessary to optimize cure rates.
The extent and timing of surgical debridement necessary
to maximize outcomes of mucormycosis has never been
defined. Data from a recent retrospective review of patients
with rhino-orbital-cerebral mucormycosis [20￿￿] support the
use of intraoperative frozen sections to delineate the
margins of infected tissues so that uninvolved tissues can
be spared from debridement. The use of calcofluor
fluorescence microscopy has also been reported to increase
the sensitivity of frozen sections for guiding extent of
surgical revision [33].
Antifungal Therapy
First-Line Monotherapy Options
In general, primary antifungal therapy for mucormycosis
should be based on a polyene, if possible. Although
amphotericin B deoxycholate (AmB) was the cornerstone
of mucormycosis therapy for decades, lipid formulations
of AmB are significantly less nephrotoxic and can be
safely administered at higher doses for a longer period of
time than AmB [20￿￿, 34]. Furthermore, treatment of
mucormycosis with liposomal amphotericin B (LAmB)
was associated with a 67% survival rate, compared to 39%
survival when patients were treated with AmB (p=0.02)
[9]. Multiple other, more recent case series also found
initial therapy with LAmB to be substantially more
effective than other options [13, 35, 36]. Therefore, most
experts now prefer to use lipid polyenes rather than AmB
for the treatment of mucormycosis.
Available data indicate advantages of LAmB over
amphotericin B lipid complex (ABLC) for the treatment
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in rabbit brain were fivefold above ABLC levels [37].
Furthermore, while similarly effective in neutropenic mice,
LAmB was markedly superior to ABLC in diabetic
ketoacidotic (DKA) mice infected with Rhizopus oryzae,
primarily because of superior clearance of fungus from the
brain [38]. These animal studies are complemented by a
recent, relatively small retrospective case series, in which the
outcomes of patients with rhino-orbital-cerebral mucormy-
cosis were found to be worse when ABLC was used as
initial therapy versus AmB or LAmB [20￿￿].
In contrast, a recent murine study found that ABLC
achieves superior lung levels than LAmB, resulting in
superior clearance of fungus from the lungs [39]. When a
higher dose of LAmB was used than ABLC, the efficacy
was similar. No clinical studies are available yet to validate
these intriguing murine data.
In the absence of definitive data on dose selection, 5–
7.5 mg/kg/d of lipid polyenes are reasonable for most cases
of mucormycosis. A recent randomized study of 339
patients with various mold infections found no clinical
benefit of LAmB dosed at 10 mg/kg/d versus 3 mg/kg/d [40].
However, there were only five total cases of mucormycosis
in the study, none of which involved the CNS. Given the low
CNS penetration of polyenes, some experts prefer dose
escalation to 10 mg/kg/d of LAmB for CNS mucormycosis.
Higher doses of LAmB do not result in pharmacokinetic
advantage compared to 10 mg/kg/d [41].
Fluconazole, voriconazole, and itraconazole do not have
reliable activity against mucormycosis [42–52]. The
reported in vitro minimum inhibitory concentration for
90% of organisms (MIC90) of posaconazole against the
Mucormycotina has ranged from 1 μg/mL to ≥4 μg/mL
[42, 53–56]. However, in patients with febrile neutropenia
or invasive fungal infections, posaconazole dosed at
400 mg twice daily resulted in serum levels less than
1 μg/mL, with considerable variability [57–59]. These data
raise concerns about the reliability of achieving adequate in
vivo levels of posaconazole to treat mucormycosis. Fur-
thermore, posaconazole is relatively ineffective for the
treatment of mucormycosis in pre-clinical animal models
[50, 60–62]. The efficacy of posaconazole as a treatment
option is further called into question by reports of
mucormycosis developing as a breakthrough infection
while on posaconazole prophylaxis [63–65]. Thus, posaco-
nazole cannot be recommended as a first-line treatment for
mucormycosis.
In contrast, van Burik et al. [66] reported 60% response
rates (45% partial response, 15% complete response) for
salvage therapy in patients with mucormycosis who were
refractory to or intolerant of polyenes. Greenberg et al. [67]
reported similar results. Hence, posaconazole is an option
for salvage therapy for these infections.
Combination Antifungal Therapy for Mucormycosis
It is now known that R. oryzae expresses the target
enzyme for echinocandins [68]. In DKA mice infected
with R. oryzae, combination caspofungin plus ABLC
therapy markedly improved survival compared to either
monotherapy or placebo [69]. Combination therapy with
LAmB plus either micafungin or anidulafungin was also
synergistic in either neutropenic or DKA mice with
disseminated mucormycosis [70].
In a recent retrospective review from two institutions,
combination polyene-caspofungin therapy was associated
with significantly improved outcomes in patients with
rhino-orbital and rhino-orbital-cerebral mucormycosis
compared to polyene monotherapy [20￿￿]. Most of the
patients were diabetic, although some patients in the series
had neutropenia or were solid-organ transplant recipients.
In multivariate analysis, only combination therapy was
significantly associated with superior outcomes (OR =
10.9 for success vs monotherapy, p=0.02).
Echinocandins have extremely favorable toxicity profiles.
Furthermore, at an average hospitalization cost of ~$100,000
p e rc a s eo fm u c o r m y c o s i s[ 71], addition of an echinocandin
at ~$100 per day for 2–4 weeks would increase hospital
costs by a small amount (ie, <3%). Thus, neither toxicity nor
cost is a compelling reason to avoid combination polyene-
echinocandin therapy for patients with mucormycosis. If
used as combination therapy, echinocandins should be
administered at standard doses—dose escalation is not
recommended, due to paradoxical loss of efficacy during
murine mucormycosis at doses ≥3m g / k g / d[ 68, 70]. A large-
scale, definitive, phase 3 clinical trial is necessary to
determine if combination lipid polyene-echinocandin therapy
is superior to monotherapy.
The central role of iron in pathogenesis of mucormycosis
has been confirmed based on in vitro and in vivo animal
models, and retrospective human studies [22, 23, 24￿￿, 72–
75, 76￿￿]. The requirement for iron acquisition for R. oryzae
growth and pathogenesis suggested that abrogation of iron
uptake could be an important therapeutic adjunct for
mucormycosis infections. Indeed, the iron chelators defer-
iprone and deferasirox, the latter of which is approved by
the US Food and Drug Administration to treat iron overload
in transfusion-dependent anemias [77], improved survival
in rodents with mucormycosis [24￿￿, 72, 74]. Deferasirox
was cidal for 28 of 29 clinical isolates of Mucormycotina in
vitro, with an MIC90 of 6.25 μg/mL [34￿￿]. The drug
exhibited time-dependent killing, with cidality occurring at
12–24 h of drug exposure. Based on trough serum levels of
greater than15 μg/mL in patients treated with deferasirox at
20 mg/kg/d, it should be feasible to maintain serum levels
in excess of the MICs of Mucormycotina throughout the
entire dosing interval [78, 79].
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as effective as LAmB therapy, and combination deferasirox-
LAmB therapy synergistically improved survival (80%
survival for combination vs 40% for either monotherapy vs
0% for placebo) [24￿￿]. In particular, combination therapy
resulted in a 100-fold decrease in brain fungal burden
compared to monotherapy. Based on these animal data,
deferasirox has been used off label as adjunctive therapy for
mucormycosis patients, both when it was the first agent
prescribed temporally and in salvage situations [80, 81].
Although limited open-label clinical experience has not
revealed substantial toxicity of the addition of deferasirox
to a polyene or posaconazole-based backbone regimen, a
recently completed phase 2, double-blind, randomized,
placebo-controlled trial of adjunctive deferasirox therapy
failed to demonstrate a benefit of the combination regimen in
patients with mucormycosis.
The toxicities of deferasirox therapy in nonhuman
primates and in clinical trials have been extensively
reviewed [77, 82, 83], and are beyond the scope of the
current article. However, the primary toxicity of concern for
the treatment of mucormycosis is renal failure. Elevations
in creatinine occurred in up to one third of patients in
deferasirox clinical trials [82, 84], but were usually mild
and almost always reversible upon cessation of the drug.
There have been rare, postmarketing reports of severe acute
renal failure resulting in hemodialysis or death in patients
taking deferasirox [85]. However, these patients typically
had other underlying risk factors for renal failure. Therefore,
the contribution of deferasirox to the renal failure in these
cases is unclear. Until more data are available, deferasirox
should be used cautiously in the setting of mucormycosis, as
toxicities are not well characterized.
No clinical data exist to address the role of combination
posaconazole-polyene therapy for mucormycosis. However,
two recent pre-clinical studies evaluated the efficacy of
posaconazole combination therapy during murine mucor-
mycosis. In the first study, Rodriguez et al. [61] found that
combining posaconazole with AmB enhanced the survival
of neutropenic mice infected with R. oryzae only when
compared to a subtherapeutic dose of AmB monotherapy
(0.3 mg/kg/d). In contrast, combination therapy was of no
advantage compared to AmB monotherapy at a standard
dose (0.8 mg/kg/d). Similarly, we recently reported that
combination posaconazole plus LAmB was of no benefit
compared to monotherapy with LAmB alone in either
neutropenic or DKA mice with mucormycosis [62]. Based
on available data, posaconazole does not have a clear role
as adjunctive therapy in combination with lipid polyenes.
Ben-Ami et al. [86] recently reported that the antibacterial
agent, colistin, has activity against the Mucorales. Colistin
was cidal in vitro, although regrowth of the fungus occurred
unless subinhibitory AmB was added for synergy. Colistin’s
mechanism of action appeared to involve disruption of the
cytoplasmic and intracellular vacuolar membrane integrity.
The drug had limited activity as a prophylactic agent during
inhalational challenge, but did not have systemic therapeutic
activity. Its potential role as a second agent in a combination
regimen merits further study.
Proinflammatory cytokines, such as interferon (IFN)-γ
and granulocyte-macrophage colony-stimulating factor
(GM-CSF), enhance the ability of granulocytes to damage
the agents of mucormycosis [87]. Adjunctive immune
therapy with recombinant granulocyte colony-stimulating
factor (G-CSF) and GM-CSF, or with recombinant IFN-γ,
has been used successfully in conjunction with lipid
formulations of amphotericin B in treatment of mucormy-
cosis [88–90]. Whether recombinant cytokines have a role
in the primary treatment of mucormycosis in immunocom-
promised patients is not well-defined.
G-CSF-mobilized granulocyte transfusions have been
increasingly used for refractory mycoses, including mucor-
mycosis [91]. Although the reported experience in manage-
ment of mucormycosis with granulocyte transfusions is
limited, such transfusions use may contain the infection
and be life-saving in persistently neutropenic hosts with this
infection. Finally, based on limited experimental and clinical
data, hyperbaric oxygen therapy may be also useful in
centers with the appropriate technical expertise and facilities
[92].
Salvage Therapy
Posaconazole or deferasirox are reasonable salvage options
for patients with mucormycosis refractory to or intolerant of
polyene therapy. Substantially more clinical data are available
for posaconazole in this setting [66, 67]. Posaconazole
appears to be quite safe despite dosing for months to years
of administration [66, 67].
Experience is limited with deferasirox as salvage therapy.
However, in case series and case reports, its addition to
patients progressing on previous therapy has resulted in
favorable outcomes without substantive toxicity [80, 86,
93]. If deferasirox is used, it should be used cautiously and
with regular monitoring of renal and hepatic function.
Administration at a dose of 20 mg/kg/d for 2–4w e e k s
is reasonable for salvage therapy, because in pre-clinical
studies of non-iron-overloaded primates, deferasirox
toxicity increased beyond 4 weeks of therapy [83].
G-CSF-mobilized granulocyte transfusions may provide
additional support for persistently neutropenic patients until
recovery from neutropenia. Administration of GM-CSF or
IFN-γ may further augment host response and antifungal
effect in non-neutropenic patients with refractory infection.
In a recent murine study, addition to LAmB therapy of GM-
426 Curr Infect Dis Rep (2010) 12:423–429CSF, but not IFN-γ, improved the survival of mice with
mucormycosis [94].
Conclusions
In recent years, numerous new options for the treatment of
mucormycosis have become available. Lipid formulations
of amphotericin are currently the preferred first-line
treatment for mucormycosis, with a possible preference
for liposomal amphotericin for CNS infection. The possibility
of combination therapy with lipid amphotericin B and an
echinocandins or iron-blocking strategy merits additional
investigation. Salvage therapy options are numerous, includ-
ing posaconazole, deferasirox, adjunctive cytokine therapy,
and hyperbaric oxygen. Underlying all successful antifungal
use isthe needtoreverse underlyinghostdefects predisposing
to infection, surgically debride necrotic tissue whenever
possible, and make an early diagnosis to facilitate rapid
initiation of antifungal therapy.
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